{
    "organizations": [],
    "uuid": "605f86d69b8fa750df45ce554e6c35161358617d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-exelixis-says-phase-3-imblaze370-s/brief-exelixis-says-phase-3-imblaze370-study-did-not-meet-its-primary-endpoint-of-improving-overall-survival-vs-regorafenib-idUSASC0A1A9",
    "ord_in_thread": 0,
    "title": "BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Exelixis Inc:\n* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER\n* STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL VERSUS REGORAFENIB\n* GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VERSUS REGORAFENIB\n* GENENTECH WILL FURTHER EXAMINE RESULTS FROM IMBLAZE370 AND PLANS TO PRESENT DATA AT AN UPCOMING MEDICAL MEETING Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T08:10:00.000+03:00",
    "crawled": "2018-05-10T08:25:28.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "provides",
        "update",
        "imblaze370",
        "phase",
        "pivotal",
        "trial",
        "atezolizumab",
        "cobimetinib",
        "patient",
        "heavily",
        "pretreated",
        "locally",
        "advanced",
        "metastatic",
        "colorectal",
        "cancer",
        "study",
        "meet",
        "primary",
        "endpoint",
        "improving",
        "overall",
        "survival",
        "versus",
        "regorafenib",
        "genentech",
        "informed",
        "co",
        "combination",
        "atezolizumab",
        "cobimetinib",
        "deliver",
        "improvement",
        "overall",
        "survival",
        "versus",
        "regorafenib",
        "genentech",
        "examine",
        "result",
        "imblaze370",
        "plan",
        "present",
        "data",
        "upcoming",
        "medical",
        "meeting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}